Physician profile
Amanda Eversgerd
NPI 1922560101
$3,263.73
in general payments reported to CMS, 2019-2025
31 companies · $19.03 in 2025
The $19.03 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,620 · 2022: $1,223 · 2023: $377 · 2024: $24.38 · 2025: $19.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $905.77 | 2021-2025 | |
| Lilly USA, LLC | $470.50 | 2021-2023 | Trulicity, Mounjaro, Jardiance |
| Optinose US, INC. | $187.75 | 2021-2023 | |
| Novo Nordisk INC | $187.52 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $178.83 | 2021-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $152.59 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $135.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $122.11 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $112.90 | 2021 | |
| Amarin Pharma, INC. | $100.85 | 2021 | |
| Glaxosmithkline, LLC. | $82.85 | 2022-2023 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.61 | 2022 | |
| Abbott Laboratories | $63.85 | 2022-2023 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.14 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.75 | 2022 | |
| Sunovion Pharmaceuticals INC. | $36.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $35.01 | 2021-2023 | |
| Amgen INC. | $34.62 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $32.41 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $27.67 | 2021-2022 | |
| Astellas Pharma US INC | $26.31 | 2023 | Veozah |
| Acerus Pharmaceuticals Corporation | $24.63 | 2022 | |
| Jazz Pharmaceuticals INC. | $20.38 | 2021 | |
| Biogen, INC. | $18.10 | 2021 | |
| Eisai INC. | $16.95 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.74 | 2021 | |
| Currax Pharmaceuticals LLC | $14.25 | 2022 | |
| Apria Healthcare LLC | $13.95 | 2021 | |
| Esperion Therapeutics, INC. | $13.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Eversgerd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.